Medco to Compare Effient vs. PGx-Guided Plavix in Heart Patients on Prevacid
July 28, 2010
Medco to Compare Effient vs. PGx-Guided Plavix in Heart Patients on Prevacid
Medco Research Institute announced this week that it is sponsoring a study to determine the optimal antiplatelet treatment for patients who are also using a proton pump inhibitor for the treatment of heartburn. The study will involve genetic testing to establish which patients can respond to Plavix.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Medco Study to Gauge Whether PGx-Based Plavix Dosing is as Effective as Higher-Priced Effient
October 21, 2009 / Pharmacogenomics Reporter - Study: Higher Plavix Dose Doesn't Improve Response for CYP2C19*2 Carriers; Effient May Be Best Option
April 4, 2012 / Pharmacogenomics Reporter - New Data on CYP2C19 Loss-of-Function Alleles Questions Impact of Plavix PGx Testing
September 1, 2010 / Pharmacogenomics Reporter - Study Points to Role of ABCB1 Gene Alterations in Plavix-Treated Patients' Cardiovascular AEs
March 17, 2010 / Pharmacogenomics Reporter - Following Merger, Express Scripts May Cut Back Medco's Personalized Medicine Programs
May 9, 2012 / Pharmacogenomics Reporter